Levetiracetam reduces frequency and duration of epileptic activity in patients with refractory primary generalized epilepsy  by Rocamora, R. et al.
Seizure (2006) 15, 428—433
www.elsevier.com/locate/yseizLevetiracetam reduces frequency and duration
of epileptic activity in patients with refractory
primary generalized epilepsy
R. Rocamora *, K. Wagner, A. Schulze-BonhageEpilepsy Center, University of Freiburg, Breisacher Str. 64, D-79106 Freiburg, Germany










Purpose: Levetiracetam (LEV) is a new antiepileptic drug highly effective as add-on
treatment in refractory partial epilepsies. In animal models, LEV is effective against
absence seizures. A limited number of case reports and series indicate that LEV
reduces seizure frequency in patients with generalized epilepsies.
Method: We evaluated with continuous EEG eight adult patients with idiopathic
generalized epilepsy (IGE). All patients were refractory to the conventional therapy
for IGE. Four patients received LEVas add-on therapy, and in four, a conversion to LEV
monotherapy was undergone. Epileptic activity was analyzed in order to determine
spike-wave density as well as median and maximal duration of spike-wave discharges.
Each patient underwent a 24 h EEG baseline monitoring before starting LEV therapy. A
second 24 h EEG examination was performed after a mean follow-up period of 136
days.
Results: Spike-wave density (spikes/h) was reduced by 78% after LEV administration.
Median spike-wave duration decreased by 72% ( p < 0.05). Maximal spike-wave
duration was 6 s before, and 1.5 s after LEV with a percentage change of 81%
( p < 0.05). The four patients on LEV monotherapy evidenced also a considerably
improvement after conversion.
Conclusions: This study showed that LEV produces a consistent long-term reduction
of interictal epileptic activity in patients with refractory IGE. The reduction in the
spike-wave activity additionally correlated with a clinically relevant antiepileptic
effect. Our results support the concept that LEV could be an alternative therapy in
primary generalized epilepsies.
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Levetiracetam (LEV) is a novel antiepileptic drug
(AED) which has been released as an adjunctive
therapy for partial epilepsies. Its chemical structure
is similar to piracetam and unrelated to other AEDs.
LEV specifically binds to the synaptic vesicle protein
SV2A in the brain, and thereby it is supposed to exert
its anticonvulsant effect by modulating calcium-
dependent exocytosis of synaptic vesicles at axon
terminals.1
LEV has shown antiepileptic efficacy both in ani-
mal models of focal2 and generalized3 epilepsies.
Although controlled clinical trials in humans have
focused on patients with focal epilepsy,4,5 prelimin-
ary evidence suggests LEV may also have an effect
on idiopathic generalized epilepsy (IGE).6 A study
with regard to the effect of LEV on epileptic dis-
charges in the EEG has reported a reduction of spike
frequency in focal epilepsy,7 and preliminary recent
reports have suggested that a similar effectmay also
be observed in idiopathic generalized epilepsy.8,9
In our study, in addition to self-reported clinical
information, we analysed long-term EEG recordings,
which offer the advantage of an objective measure
of ongoing epileptic activity over the whole sleep-
wave-cycle. Self-reporting of seizures may grossly
underestimate particularly the frequency of
absence seizures or nocturnal seizures. Considering
that brief episodes of impaired consciousness are
also not accurately quantified by extern observa-
tion, assessment with long-term EEG monitoring
provides a more reliable documentation of clinical
response after treatment initiation.10
Our case series reports efficacy of LEV in the
reduction of spike-wave-bursts in patients with idio-
pathic generalized epilepsy by repeated long-term
EEG recordings prior to and after institution of LEV.
This provides further objective support to the notion
that LEV is a useful therapeutic option in this group
of patients.Table 1 Patients characteristics
Age Gender Age at first
seizure
Seizure type
Pat 1 32 F 17 GTCS; myoclonic;
absence
Pat 2 29 M 16 GTCS; myoclonic
Pat 3 32 F 12 GTCS; absence
Pat 4 31 F 15 GTCS; myoclonic;
absence
Pat 5 19 M 13 GTCS
Pat 6 15 F 13 GTCS; rare
absences
Pat 7 25 M 24 GTCS
Pat 8 29 F 15 GTCS; rare
absencesMethod
We retrospectively analysed long-term EEG record-
ings from a group of adult patients suffering from
refractory IGE before and after antiepileptic ther-
apy with LEV. Classification was based on interictal
routine EEG recordings demonstrating generalized
spike-wave EEG patterns on a normal background
and on additional clinical information including nor-
mal neurological status, seizure types, and normal
MR imaging results. All patients suffered from
primarily generalized tonic—clonic seizures (GTCS),
additional seizure types were absences and/ormyoclonic seizures. There were no additional med-
ical or psychiatric illnesses.
Eight consecutive patients (three males, five
females, mean age 27 years, mean duration of
epilepsy 10.8 years; Table 1) were selected for
treatment with LEV due to deficient seizure control
with prior AEDs.
Each patient enrolled in this protocol was
planned to have two 24 h-long-term EEGs before
and after LEV therapy in order to determine and
quantify the presence of ongoing generalized epi-
leptic discharges. The time of performance of the
second long-term EEG control was decided on clin-
ical grounds and it was performed after a mean
follow-up period of 136 days.
An informed consent was previously given and no
patient was excluded. Prior to LEV administration,
treatment consisted of valproate-monotherapy
(600—1325 mg/day; three patients), topiramate-
monotherapy (250 mg/day, one patient), oxcarbaze-
pine-monotherapy (1350 mg/day, in this patient the
medicament was removed prior to the first 24 h-
EEG), lamotrigine-monotherapy (1000 mg/day, one
patient), and valproate in combination with lamo-
trigine (LTG: 275—300 mg/day; VPA: 2000—2500 mg/
day, two patients).
Patients received LEV at dosages of 1000—
3000 mg/day (Table 2). Four patients were treated
with LEV in an add-on basis (1500—2000 mg/day).
These patients had already been on polytherapy
consisting of two or more AEDs. Four other patients
who previously had been only on monotherapy were
converted to LEV monotherapy (1000—3000 mg/
day). All patients were asked retrospectively for
their seizure frequency in the time before the first
long-term EEG was done and LEV added. After that,
they were asked for the seizure frequency after LEV
therapy and immediately before the second long-
term EEG.
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Table 2 Previous AEDs and at first and second 24 h-EEG
Previous AED AEDs at 1st EEG
(mg/day)




Pat 1 VPA PB ESM LTG CLB VPA 800 VPA 800 + LEV 2000 >50% reduction
Pat 2 VPA CBZ LTG LTG 1000 LTG 700 + LEV 1500 Seizure-free
Pat 3 VPA LTG VPA 2500 + LTG 275 LTG 300 + LEV 2000 Seizure-free
Pat 4 CBZ VPA LTG VPA 2000 + LTG 300 LTG 425 + LEV 2000 Worsening of
myoclonic seizures
Pat 5 VPA VPA 1325 LEV 3000 Seizure-free
Pat 6 CBZ OXC LTG OXC 1350a LEV 1000 Seizure-free
Pat 7 VPA CBZ LTG VPA 600 LEV 3000 >50% reduction
Pat 8 ESM VPA TPM TPM 250 LEV 1500 Seizure-free
a AED suspended before EEG-study.Electroencephalographicanalysis includedavisual
score of definite spikes, polyspikes, sharp-waves, and
spike-and-wave complexes of the entire 24 h EEG.
Criteria for the identification of epileptic discharges
were adapted from those of Gloor and included (a)
triangular paroxysmal waves with an amplitude of at
least twice that of the preceding 5 s of background
activity, lasting<80 ms (spikes) or 80—120 ms (sharp-
waves) followed (or not) by a slow after potential
(slow-wave) and (b) presence of a field.11 All spikes
within polyspikes, sharp-waves and spike-and-wave
complexes were counted as individual spikes. For
each burst the total duration and the number of
discharges inside were measured. Based on these
data, median and maximum spike-wave-duration
were calculated. The spike-wave density was obtain-
ed from the ratio of total amount of spikes in 24 h.
Spike-wave burst duration was measured in sec-
onds, and the spike-wave density (frequency) in
spikes/h. One of the authors (R.R.), a board-certi-
fied epileptologist, performed visual detection and
analysis of IEDs. Although the visual analysis was not
performed blinded, the author did not know the
clinical effect of LEV in each patient at the time of
EEG evaluation.Figure 1 Patients’ individual effects on spike-wave density, m
and after (2) administration of LEV.The effect of LEV on median spike-wave burst
duration, on maximum burst duration, and spike-
wave density was evaluated. Changes following
institution of LEV were assessed using 2-tailed
non-parametric tests (Wilcoxon signed rank test);
differences were regarded as significant at p < 0.05.
Descriptive statistic was presented as median and
percentage change.Results
According to inclusion criteria, all of our patients
had normal background EEG activity. Epileptic dis-
charges consisted of irregular spike-and-waves,
polyspike-and-wave complexes, 3-Hz spike-and-
waves, and isolated spikes. There were no signs of
localized slow waves or any evidence of focal epi-
leptiform activity.
Analysis of the effects of LEV on EEG
discharges
Spike-wave median density (spikes/h) was 24.5
before and 3.1 after LEV institution; the decreaseedian andmaximum spike-wave burst duration before (1)
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Figure 2 Boxplots of percentage change from baseline
(Before LEV) for all variables: (*), extreme value; (8),
outlier.was 78% from baseline (p = 0.123, n.s.). One patient
(Pat 2) showed an increase in spike-wave density but
he remained seizure-free at follow-up examination
3 months later.
Median spike-wave burst duration was 1 s before
and 0.2 s after LEV-therapy, corresponding to a
reduction from baseline by 72% across the whole
group (p < 0.05).
Pat 4 showed no improvement during the 24 h,
which correlated with a clinical seizure frequency
worsening (Fig. 1). Improvement in the total group
was more marked during wakefulness than during
sleep.
Maximum spike-wave burst duration was 6 s
before, and 1.5 s after LEV, corresponding to a
decrease by 81% from baseline values (p < 0.05).
Again, this parameter was considerably reduced in
seven out of eight patients except Pat 2.
Mean change in all variables are summarised in
Fig. 2.
Clinical effects
Patient 1, a 32-year-old woman with the diagnosis of
juvenile myoclonic epilepsy (JME), presented daily
uncontrolled myoclonic seizures of difficult treat-
ment, with duration of more than 30 min without
interruption (myoclonic status). After the treat-
ment with LEV 2000 mg a day, a seizure frequency
reduction of approximately 50% was observed. Due
to the difficult control of the case, the second long-
term EEG was performed 2 weeks after the first one
and confirmed the positive effect of LEV therapy.In a 29-year-old male patient (Pat 2) with diag-
nosis of epilepsy with GTCS on awakening with rare
myoclonies, rhythmic generalized spike-/sharp-
wave complexes with a duration longer than 52 s
were described in the routine electroencephalo-
graphic controls. After the addition of LEV, the
patient remained seizure-free for a period of 3
months when the second EEG was performed.
Patient 3, a 32-year-old female with diagnosis of
juvenile absence epilepsy remained seizure-free
after add-on LEV therapy at the second long-term
EEG 15 months later.
Patient 4 did not respond but instead had an
increase in myoclonic seizures, which corre-
sponded to an increase in median sharp-wave
duration as reported above (Table 2). This patient
was a 31-year-old woman with an idiopathic gen-
eralized epilepsy (Janz-syndrome) since age 15.
She suffered in the first years of disease only from
absences, but thereafter developed also myoclonic
and tonic—clonic seizures in increasing frequency.
In EEG typical generalized 3 Hz spike-wave com-
plexes were observed. Directly after LEV therapy
onset a clinical improvement with disappearance
of myoclonic seizures was initially observed, how-
ever, during the course of 4 weeks, a progressive
deterioration with increase of myoclonic seizures
and GTCS was observed, which lead to withdrawal
of LEV. It is not possible to rule out that such
deterioration was caused for the replacement of
valproate by levetiracetam. Nonetheless, in cases
5 and 6 such substitution was successful. Due to
the poor clinical control, the second long-term
EEG was realized 1 month after the change of
medication.
Patient 5, a 19-year-old male with diagnosis of
IGE with uncontrolled GTCS became seizure-free
after the change from VPA to LEV 3000 mg a day.
The second EEG was performed almost a year after
they begin with LEV-monotherapy.
Patient 6, a 15-year-old female, presented also
an IGE with principally GTCS (almost one every 2
months) and scarce episodes of absences. She has
been treated in the past with LTG, CBZ, and OXC
due to an erroneous epilepsy classification. In
this patient, treatment with OXC was suspended
under video-EEG control 72 h before the first EEG
was performed. After the begin of LEV 1000 mg a
day in monotherapy, the patient stayed seizure-
free at the second long-term EEG-control 1 month
later.
Patient 7, a 25-year-old male with IGE suffered
GTCS in a frequency of almost one per month. In the
second EEG control, 4 1/2 months later, the patient
reported only two seizures under therapy with LEV
3000 mg in monotherapy.
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IGE with GTCS and scarce absences. The frequency
of GTCS was one every 3 months. This patient
remained continuously seizure-free after intro-
duction of LEV both before the second long-term
EEG performed 6 weeks later and thereafter under
LEV monotherapy for a follow-up period of 6
months.
In resume, LEV therapy was well tolerated in all 8
patients. All patients except one reported a signifi-
cant clinical improvement in comparison to baseline
based on seizure records. Five of them became
seizure-free; two showed a reduction by more than
50% in seizure frequency.Discussion
Our case series shows a significant effect of LEV on
the presence of generalized epileptic activity in
patients with refractory IGE. Nevertheless, the rela-
tionship between interictal and ictal activity in
patients with epilepsy has been object of contro-
versy in the past. Former published data have shown
a weak association between interictal epileptiform
activity and seizure frequency12,13 when analyzing
short routine EEG examinations.
In this regard, some distinctions should be made
also between localization-related and generalized
epilepsies. The transitions of interictal to ictal pat-
terns are normally unfamiliar for the most of the
clinical neurophysiologists. In focal epilepsies, the
clinical relevance of the frequency of interictal
epileptic discharges (IEDs) has not been clearly
demonstrated until now. Although some evidence
suggest that abnormal responses may occur with
interictal focal spikes,14 a positive correlation
between IEDs frequency and clinical seizure fre-
quency lacks. Only when repetitive spikes, sharp
waves or rhythmic waves occur, clinically apparent
seizures appear.15 Thus, in focal seizures, ‘‘prolon-
gation’’ of IEDs is not the most important determi-
nant for transition to clinical activity.
In generalized epilepsies instead, the distinction
between interictal bursts of generalized spike-wave
activity and absence seizures remains confusing.
Moreover, discrete interictal epileptic discharges
may have clinical relevance.
Studies have demonstrated a delayed auditory
reaction in about 80% of responses within 2 s of the
onset of generalized activity.16,17 An important
finding was that responsiveness was equally
impaired in shorter (>3 s) and longer bursts
(<3 s). Duration of bursts remains important,
because longer bursts imply longer periods of
altered responsiveness. This fact has not beendemonstrated to be relevant in focal epilepsies.
In idiopathic generalized epilepsies what is called
interictal or ictal activity depends largely on the
instrument of measure. If assessed with sufficient
sensitivity, generalized discharges are frequently
associated with transient cognitive impairments
(TCI).18 This phenomenon of TCI may be found in
up to 50% of patients who show discharges during
testing indicating that ‘‘subclinical’’ generalized
epileptic discharges certainly have clinical corre-
lates. This may contribute to the cognitive and
behavioural problems of some people with epi-
lepsy.19 Accordingly, a reduction of the amount of
interictal epileptiform activity is a possible reason
for observed behavioural and alertness improve-
ment after therapeutic changes.20
In the present case series, spike-wave density
reflecting the total amount of sharp-waves in 24 h
tended to be reduced after LEV administration,
although not statistically significant (p = 0.123).
In average a percentage change reduction by 78%
of the interictal activity was assessed, but two out
of eight patients showed no substantial reduction.
Levetiracetam significantly reduced spike-wave
burst duration in seven out of eight patients as
demonstrated by long-term EEG monitoring
(p < 0.05). Only one patient evidenced a deteriora-
tion of this parameter, which correlated with an
increase in the frequency of myoclonic seizures and
GTCS.
Before LEV treatment, maximum spike-wave
burst duration within the group was 6 s as opposed
to 1.5 s with LEV ( p < 0.05). Only one patient
evidenced persistent epileptic activity up to 5.6 s
duration, which may be assumed to be associated
with persistent impairment of consciousness and/or
transient cognitive impairment.
Reduction of epileptic activity on EEG correlated
with an improvement in the clinical self-reported
seizure frequency. In our group, five out of eight
patients became seizure-free, two others showed
more than 50% of seizure frequency reduction, and
only one evidenced a clinical worsening in parallel
with EEG deterioration. Therefore, our study adds
further evidence that in idiopathic generalized epi-
lepsies, an evaluation of spike-burst duration in
long-term EEG shows a good correlation to clinical
outcome parameters and can be a valuable surro-
gate for evaluating the efficacy of antiepileptic
medications.
Our results closely correspond to recently pub-
lished short communications that described positive
effects of LEV on generalized epileptic discharges in
patients with IGE.8,9 This correlates also with
reports on clinical improvement after LEV therapy
in patients with generalized epilepsies.6,21
Levetiracetam reduces epileptic activity 433Actually, the number of patients included in our
analysis of LEV efficacy in IGE does not allow us to
draw conclusions regarding specific epilepsy syn-
dromes; it cannot be ruled out that LEV exerts
differential effects upon different forms of IGE. In
addition, the patients reported here certainly are
biased sample of difficult-to-treat cases, as they had
not responded to initial antiepileptic regimens.
IGEs show usually a favorable response to medical
treatment. Indeed, some of these forms remit spon-
taneously, but others tend to persist lifelong and
require indefinite AED therapy. Until now, there is
scarcity on information on therapeutic strategies
which are clinically useful in refractory IGE.22 In
IGE, VPA is usually regarded as the drug of choice,
but there is a minority of patients who do not
respond well to VPA or in whom VPA is considered
contraindicated. Lamotrigine is increasingly used
for many refractory patients with IGE with satisfac-
tory results. Both topiramate and levetiracetam
may also be an appropriate choice in this situation,
but their efficacy spectrum remains to be investi-
gated in more detail. Moreover, the fact that LEV
was effective in these more severe forms of IGEs
may be of particular clinical significance.Conclusions
In our series, LEV proved efficacious reducing gen-
eralized epileptic activity both as add-on and as
monotherapy in a difficult-to-treat sample of IGE
patients. Duration of spike-wave-bursts correlated
well with clinical self-reported seizure frequency in
our patients. The overall good efficacy of LEV is in
well accordance with recent other case series and
gives additional support to the need for larger pro-
spective randomised clinical trials in order to verify
the clinical efficacy of LEV in primary generalized
epilepsies.Acknowledgment
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